AI synthesizes the latest research and builds a custom supplement stack, lifestyle plan, and biomarker targets — personalized to your age, goals, and budget.
Generate My Protocol →Interventions with replicated randomized controlled trials in humans. High confidence, broad consensus. Foundation of any serious protocol.
Strong animal models plus human observational support. Effect direction established, magnitude uncertain in humans.
Mechanistically compelling, early human data or first trials starting. High upside potential, higher risk profile. Monitor closely.
Answer 6 questions. Your personalized protocol generates instantly.
For informational purposes only. Consult your physician before starting any new supplement regimen. Always review for drug interactions.
The full protocol includes 90-day implementation timeline, supplement sourcing guide with quality ratings, interaction checker, and monthly update alerts as new research publishes.
We continuously synthesize peer-reviewed research, preprints, and clinical trial data to keep your protocol current.
ER-100 by Life Biosciences receives FDA IND approval — first epigenetic reprogramming compound entering human clinical trial. Added as Tier 3 watch category.
Dasatinib + Quercetin (popular senolytic combo) linked to myelin loss in mouse model. Removed from default protocols; flagged for users currently taking it.
GLP-1 agonists now show epigenetic age reduction + CV mortality benefits. Added with mandatory resistance training co-requirement to offset sarcopenia risk.
David Sinclair's 2026 stack update adds Taurine 2g/day and reintroduces ALA. Rapamycin weekly dosing confirmed. NMN maintains Tier 2 status.